Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2014

01-07-2014 | Letter

Autoantibodies and type 1 diabetes: are we still in the cave of an ancient myth?

Author: Alfonso Galderisi

Published in: Diabetologia | Issue 7/2014

Login to get access

Excerpt

To the Editor: Autoimmunity has been an undisputed boundary line between type 1 diabetes and other forms of diabetes, including type 2 and MODY, observed in paediatric patients [1], although recent evidence should lead us to reconsider this boundary carefully. …
Literature
1.
Wolfsdorf J, Craig ME, Daneman D et al (2009) ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes 10(Suppl 12):118–133PubMedCrossRef
2.
Donath MY, Hess C, Palmer E (2014) What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia 57:653–655PubMedCrossRef
3.
Krogvold L, Edwin B, Buanes T et al (2014) Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 57:841–843PubMedCrossRef
4.
5.
Brooks-Worrell B, Narla R, Palmer JP (2013) Islet autoimmunity in phenotypic type 2 diabetes patients. Diabetes Obes Metab 15(Suppl 3):137–140PubMedCrossRef
6.
d'Annunzio G, Marchi M, Aloi C, Salina A, Lugani F, Lorini R (2013) Hyperglycaemia and β-cell antibodies: is it always pre-type 1 diabetes? Diabetes Res Clin Pract 100:e20–e22PubMedCrossRef
7.
Irgens HU, Molnes J, Johansson BB et al (2013) Prevalence of monogenic diabetes in the population-based Norwegian Childhood Diabetes Registry. Diabetologia 56:1512–1519PubMedCrossRef
8.
Jaeger C, Hatziagelaki E, Petzoldt R et al (2001) Comparative analysis of organ-specific autoantibodies and celiac disease-associated antibodies in type 1 diabetic patients, their first degree relatives, and healthy control subjects. Diabetes Care 24:27–32PubMedCrossRef
9.
Murphy R, Ellard S, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4:200–213PubMedCrossRef
Metadata
Title
Autoantibodies and type 1 diabetes: are we still in the cave of an ancient myth?
Author
Alfonso Galderisi
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3261-5

Other articles of this Issue 7/2014

Diabetologia 7/2014 Go to the issue

Article

Pank1 deletion in leptin-deficient mice reduces hyperglycaemia and hyperinsulinaemia and modifies global metabolism without affecting insulin resistance

Article

Common genetic variation in the glucokinase gene (GCK) is associated with type 2 diabetes and rates of carbohydrate oxidation and energy expenditure

Article

Multiple behaviour change intervention and outcomes in recently diagnosed type 2 diabetes: the ADDITION-Plus randomised controlled trial

Article

Doc2b enrichment enhances glucose homeostasis in mice via potentiation of insulin secretion and peripheral insulin sensitivity

Letter

Type 1 diabetes as an autoimmune disease: the evidence

Article

IL-6-dependent proliferation of alpha cells in mice with partial pancreatic-duct ligation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits